BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has been added to the NASDAQ Biotechnology Index® (Symbol: NBI), effective prior to the stock market open today, November 21, 2011.
“We are delighted that BioSante has been added to the NASDAQ Biotechnology Index, as it recognizes our established role in the biotechnology industry, adds greater visibility for our company and could lead to a broader stockholder base”
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market capitalization-weighted index, and the index securities are evaluated semi-annually in May and November.
"We are delighted that BioSante has been added to the NASDAQ Biotechnology Index, as it recognizes our established role in the biotechnology industry, adds greater visibility for our company and could lead to a broader stockholder base," stated Phillip Donenberg, BioSante's senior vice president of finance and chief financial officer.
Nuclera joins Tech Nation’s Future Fifty program